evitria AG announces license of mAbsolve STR technology
evitria AG, the market-leading transient CHO expression service provider, today announces the closing of a license agreement with ...
Read More mAbsolve Quarterly Company Update
This quarter saw our publication on the STR silencing technology accepted and published in PLOS ONE (see here). ...
Read More STR silencing published in PLoS ONE
We are delighted to announce that our novel STR silencing technology has been recently published in the peer ...
Read More mAbsolve Quarterly Company Update
Along with our updated website we are also launching the first edition of our company updates. We intend ...
Read More mAbsolve Launches Updated Website
When the company was founded in December 2019 we were a startup with an interesting technology in the ...
Read More mAbsolve’s STR Patent Application Published
mAbsolve’s international patent application on a novel Fc silencing technology has today been published under application number WO/2021/234402.
Read More Dr. Ian Wilkinson joins mAbsolve as Chief Scientific Officer
Starting today Dr. Ian Wilkinson joins mAbsolve as Chief Scientific Officer, having been a Founder and non-executive Director ...
Read More Prof. Geoff Hale to present at Antibody Drug Development Summit 2021
Prof. Geoff Hale, CEO of mAbsolve, will present on our novel STR Fc silencing technology at the upcoming ...
Read More mAbsolve Files International Patent Application
mAbsolve has today filed an international patent application PCT/GB2021/051233 on its novel Fc silencing technology.
Read More - « Previous
- 1
- 2
- 3
- 4
- Next »